ブライトパス・バイオ㈱
2 known investors
Brightpath Bio develops cancer immunotherapies, including an allogeneic iPS-NKT cell therapy that redifferentiates NKT cells from iPS cells to enable large-scale, uniform production from donor-derived master iPS cell banks. Its pipeline also spans gene-modified cell therapies, immune checkpoint/immune-modulating antibodies, and cancer vaccines.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does ブライトパス・バイオ㈱ do?
- Brightpath Bio develops cancer immunotherapies, including an allogeneic iPS-NKT cell therapy that redifferentiates NKT cells from iPS cells to enable large-scale, uniform production from donor-derived master iPS cell banks. Its pipeline also spans gene-modified cell therapies, immune checkpoint/immune-modulating antibodies, and cancer vaccines.
- Who are ブライトパス・バイオ㈱'s investors?
- ブライトパス・バイオ㈱'s investors include DBJ Capital, Sumitomo Mitsui Trust nvestment Co. Ltd..